Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clone3HM-MMAE
- Development stage
- Preclinical
- Lead developer
- Beijing Institute of Biotechnology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Clone3HM-MMAE is an investigational **CD33-targeting antibody-drug conjugate** developed from a fully humanized anti-CD33 monoclonal-antibody clone, Clone3HM. The antibody is conjugated through a cleavable Mal-PEG8-VC-PAB linker to the antimitotic payload monomethyl auristatin E. It is intended for treatment of CD33-positive acute myeloid leukemia, where CD33-mediated binding and internalization are intended to release MMAE intracellularly, disrupt microtubules, and induce leukemic-cell death. In MOLM13-Luc acute myeloid leukemia xenograft models, a single 5 mg/kg intravenous dose produced marked tumor suppression and prolonged survival relative to gemtuzumab-MMAE without overt body-weight loss. The candidate remains at the preclinical stage and has no assigned INN or marketed brand name.
- Other names
- Clone3-HM-MMAEClone-3-HM-MMAEClone 3-HM-MMAEClone3HM + monomethyl auristatin EClone3HM-MMAEClone-3HM-MMAEClone 3HM-MMAE
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on Clone3HM-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clone3HM-MMAE.